VMD vs. PNTG, AVAH, AGL, LFMD, FLGT, PSNL, CSTL, INNV, FTRE, and EHAB
Should you be buying Viemed Healthcare stock or one of its competitors? The main competitors of Viemed Healthcare include The Pennant Group (PNTG), Aveanna Healthcare (AVAH), Agilon Health (AGL), LifeMD (LFMD), Fulgent Genetics (FLGT), Personalis (PSNL), Castle Biosciences (CSTL), InnovAge (INNV), Fortrea (FTRE), and Enhabit (EHAB). These companies are all part of the "healthcare" industry.
Viemed Healthcare vs. Its Competitors
Viemed Healthcare (NASDAQ:VMD) and The Pennant Group (NASDAQ:PNTG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.
74.2% of Viemed Healthcare shares are owned by institutional investors. Comparatively, 85.9% of The Pennant Group shares are owned by institutional investors. 20.0% of Viemed Healthcare shares are owned by insiders. Comparatively, 5.4% of The Pennant Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Viemed Healthcare has a net margin of 5.28% compared to The Pennant Group's net margin of 3.40%. The Pennant Group's return on equity of 10.73% beat Viemed Healthcare's return on equity.
Viemed Healthcare has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, The Pennant Group has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
In the previous week, Viemed Healthcare and Viemed Healthcare both had 5 articles in the media. The Pennant Group's average media sentiment score of 0.81 beat Viemed Healthcare's score of 0.24 indicating that The Pennant Group is being referred to more favorably in the news media.
The Pennant Group has a consensus target price of $34.60, indicating a potential upside of 31.58%. Given The Pennant Group's stronger consensus rating and higher probable upside, analysts clearly believe The Pennant Group is more favorable than Viemed Healthcare.
The Pennant Group has higher revenue and earnings than Viemed Healthcare. Viemed Healthcare is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.
Summary
The Pennant Group beats Viemed Healthcare on 12 of the 15 factors compared between the two stocks.
Get Viemed Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for VMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viemed Healthcare Competitors List
Related Companies and Tools
This page (NASDAQ:VMD) was last updated on 7/3/2025 by MarketBeat.com Staff
